What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.
about
Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patientsSynergistic combinations of antifungals and anti-virulence agents to fight against Candida albicansIntensive care medicine research agenda on invasive fungal infection in critically ill patients.Intra-abdominal Candida spp infection in acute abdomen in a quality assurance (QA)-certified academic setting.Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year periodManagement of invasive candidiasis in nonneutropenic ICU patients.Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditionsIdentification of Candida species and susceptibility testing with Sensititre YeastOne microdilution panel to 9 antifungal agents.Blad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell.Combinatorial strategies for combating invasive fungal infections.Diagnostic of Fungal Infections Related to Biofilms.The current treatment landscape: candidiasis.(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.Unmet needs in the management of intra-abdominal infections.Evaluation of the (1,3)-β-D-glucan assay for the diagnosis of neonatal invasive yeast infections.Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain.Candida spp. airway colonization: A potential risk factor for Acinetobacter baumannii ventilator-associated pneumonia.Focus on infection and sepsis in intensive care patients.Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.Candida biomarkers in patients with candidaemia and bacteraemia.T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?Untargeted antifungal therapy in adult patients with complicated intra-abdominal infection: a systematic review.Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries.Profile of GenMark's ePlex® blood culture identification fungal pathogen panel.De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety.
P2860
Q26852351-EED36AA6-1007-4501-B73C-CE1C10643EE0Q28082407-45D070E7-E392-4C1D-AF6A-104F94A76018Q30235457-75A3D99C-B045-45A8-ABF4-0643104B7AB6Q33833262-850DC7DF-13C2-433F-A297-D6E83D786179Q34100598-08338868-341E-477D-8ABD-92CF8ADA6C08Q34252030-098DDC79-633C-4A28-8E8A-EA411B08A27DQ35122093-01E5A571-57A7-49BF-B903-9B06BDF7D177Q35816268-AA98990A-62F9-42EC-8673-E9095E798B1FQ36441468-E8ECC7B7-947F-43BF-A367-80EB0709CE39Q36902916-B9DF160E-6E9D-4DCD-9C6A-DBF86A9F5353Q37247203-294D2441-83AD-418F-AD40-3E6F6E645EDBQ37438608-EAC0AEF4-36E7-4FC6-843D-11A1A4E6FF7AQ37705303-642D434B-3C8A-4719-B70B-5FFE1E3A6E53Q38853348-6D98609D-F6AF-45D9-8D8F-EBFC7DE660FAQ39018200-90C3C8D9-0C6C-4DA2-80E5-4678FB9403FEQ39812922-67648FF4-708F-41BD-AAB9-117E9195914BQ40079705-551DAC13-C7C5-4D17-B564-B491BF2A0951Q40266645-275EC122-AC89-4C29-8112-493E4347DD8DQ40533714-CAA9BFC9-A8F9-493E-B4FA-37BF5DEBBAFBQ40746229-B506A155-DBB7-4F5F-A544-AB9219EFA67FQ40797788-1F8D17C7-D9C6-4F9B-A518-99CA585D14A7Q41031258-345D9301-5F6B-46CB-8861-843FC8145E89Q41038889-5BDF85C5-C621-4E8B-A3C9-742CD231A937Q41128217-85F43A0C-4C66-4541-AB5A-AC0C13807B13Q41204913-7ADC5C32-9229-4E0E-8269-7245C36963FBQ41299438-459D843D-D6B9-4A4B-AF55-88F04F38997EQ41546170-25A41226-33F9-4386-8B71-C9B57F5D3CCFQ42362382-B919C4B9-02CA-4CE1-81DA-B04ACF6600DEQ47619531-2DBE3DF5-D69A-47C0-9145-6997A096DB58Q47678193-FFC69F7F-7AFD-4E49-B05A-109370F494F1Q47749829-9789C253-C1F4-48CF-B8D6-12D0B08C2BD7Q48163160-36954329-0993-4EB3-AE86-777D4788F15BQ50128355-14F80725-961B-4285-BE51-24F78DCBD1C6Q52575674-9F6AB170-1A18-4F98-82D5-8E3A1FBBB92B
P2860
What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
What's new in the clinical and ...... is in critically ill patients.
@en
type
label
What's new in the clinical and ...... is in critically ill patients.
@en
prefLabel
What's new in the clinical and ...... is in critically ill patients.
@en
P2093
P2860
P1476
What's new in the clinical and ...... is in critically ill patients.
@en
P2093
Cristóbal León
Luis Ostrosky-Zeichner
Mindy Schuster
P2860
P2888
P304
P356
10.1007/S00134-014-3281-0
P577
2014-04-10T00:00:00Z